|

Sacubitril/Valsartan in Patients With Prosthetic Heart Valves With Heart Failure and Reduced Ejection Fraction

RECRUITINGN/ASponsored by Kafrelsheikh University
Actively Recruiting
PhaseN/A
SponsorKafrelsheikh University
Started2025-09-27
Est. completion2026-02-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07192341

Summary

This study aims to evaluate the effect of sacubitril/valsartan in patients with prosthetic heart valves with heart failure with reduced ejection fraction (HFrEF).

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Age ≥ 18 years old.
* Both sexes.
* Patients with a history of prosthetic heart valves.
* Patients diagnosed with heart failure with reduced ejection fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) ≤ 40% with New York Heart Association (NYHA) functional class II-IV.

Exclusion Criteria:

* Hemodynamic instability.
* Use of a circulatory auxiliary circulation device.
* Severe hepatic \[alanine aminotransferase (ALT) \>120 U/L\] and renal insufficiency \[estimated glomerular filtration rate (eGFR) \<30 mL/min\].
* Blood pressure \<100/60 mmHg.
* Serum potassium \>5.3 mmol/L.
* Severe pulmonary hypertension.
* Malignant arrhythmia.
* Malignant tumor.
* Known history of hereditary or primary angioedema.
* Serious adverse drug reactions or serious complications over the course of treatment.

Conditions5

Heart DiseaseHeart FailureProsthetic Heart ValveReduced Ejection FractionSacubitril/Valsartan

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.